AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04607018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMA-zeolite
Description: subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days.~Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass).
Study NCT02062619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based behavioural word reading therapy
Description: Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)
Study NCT02062619 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computer-based behavioural word reading therapy
Description: Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)
Study NCT02062619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Real tDCS 20 minutes per session, three times per week
Study NCT02062619 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS, 20 minutes per session, 3 sessions per week
Study NCT00559819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (orange juice), same volume as alcohol
Study NCT00559819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
Study NCT04207632 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin type A injection
Description: Ultrasound-guided BoNT-A injection in biceps brachii or brachialis
Study NCT02481128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without preoperative access to lymphoscintigraphy findings
Description: axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
Study NCT03494998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PAT-POPS
Description: Emergency Department-specific screening tool
Study NCT01811966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume
Study NCT01811966 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Study NCT02354430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water-exercise
Description: 1. An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.~2. One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice~3. Unsupervised water-exercises (The six AquaMama exercises)~4. Motivating weekly emails during the 12 week training period.~5. Brush up sessions is held once every month for guidance in performing the exercises.
Study NCT00396253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: 2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
Study NCT00926718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil infusion
Description: rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
Study NCT00926718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium dose + remifentanil infusion
Description: rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
Study NCT00926718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium dose + remifentanil infusion
Description: rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
Study NCT00926718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil infusion
Description: rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
Study NCT00926718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium dose + remifentanil infusion
Description: rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
Study NCT00926718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium dose + remifentanil infusion
Description: rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
Study NCT04616989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education
Description: Provide psycho-education to members of the community
Study NCT04616989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Distribution of COVID-19 leaflets to members of the community
Study NCT00699114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose as powder in gelatine capsules, single dose
Study NCT00699114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg as powder in gelatine capsules, single dose
Study NCT00699114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600 mg as powder in gelatine capsules, single dose
Study NCT00699114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: Ibuprofen 800 mg as powder in gelatine capsules, single dose
Study NCT00699114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen) 500 mg
Description: Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
Study NCT00699114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen) 1000 mg
Description: Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
Study NCT00699114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg
Description: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
Study NCT03413488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: Apply exercise and kinesio taping for intervention
Study NCT03413488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Apply only exercise intervention
Study NCT03830307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSS-2-Bridge
Description: NSS-2-Bridge auricular therapy will be given in addition to standard of care
Study NCT00169065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Study NCT00169065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study NCT04583241 — intervention group
Intervention type: OTHER
Intervention: Constitution of serum bank at D0
Description: Blood samples at Day 0 (day of surgery)
Study NCT04583241 — intervention group
Intervention type: OTHER
Intervention: Constitution of serum bank during follow-up
Description: Blood samples are obtained at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years.
Study NCT04583241 — intervention group
Intervention type: OTHER
Intervention: ELISA assays of serum markers of bone remodeling at D0
Description: Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at Day 0 (day of surgery)
Study NCT04583241 — intervention group
Intervention type: OTHER
Intervention: ELISA assays of serum markers of bone remodeling during follow-up
Description: Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years
Study NCT04583241 — intervention group
Intervention type: OTHER
Intervention: Analysis of bacterial gene expression at D0
Description: Assessement of bacterial gene expression on surgery residual tissue (bone tissue, joint fluid, fragment of prostheses) collected at Day 0 (day of the surgery)
Study NCT01649206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Radiofrequency Thermal Ablation
Description: Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
Study NCT04287582 — intervention group
Intervention type: OTHER
Intervention: Electromyographic device
Description: An 8-channel surface EMG system (DELSYS Trigno Wireless System) will be used to measure signals from muscles during stair climbing activity by surface electromyography measurements.Surface EMG measurements will be carried out during stair climbing activity without any intervention in the body. Surface EMG electrodes will be placed bilaterally in the vastus lateralis, biceps femoris, tibialis anterior and gastrocnemius medialis muscles.
Study NCT03752437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ACT (Activated Clotting Time)
Description: Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
Study NCT03752437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 300 IU of heparin
Study NCT03521440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor Massage
Description: Sessions will be conducted by a graduated therapist, experienced in Psychomotor Massage and weekly supervised by a specialist in this therapeutic approach. The Psychomotor Massage involves smoothly touching the head, upper and lower limbs, followed by micro-stretching and slow mobilisations of upper and lower limbs.
Study NCT03521440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Sessions will be conducted by a graduated therapist, experienced in Progressive Muscle Relaxation, and weekly supervised by a specialist in this therapeutic approach. The Progressive Muscle Relaxation protocol consists in tensing and releasing 16 muscle groups for several seconds, following a specific order.
Study NCT00719472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
Study NCT00719472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
Description: Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
Study NCT00719472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVP (cyclophosphamide, vincristine, prednisone)
Description: Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
Study NCT00719472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic/antipyretic and antihistamine drugs
Description: An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
Study NCT01240824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminophylline
Description: One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
Study NCT02570048 — intervention group
Intervention type: DEVICE
Intervention: Mutebutton intervention
Description: Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
Study NCT04129463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subscleral Trabeculectomy (SST) with Iris incarceration
Description: Subscleral Trabeculectomy with Iris Incarceration using iris forceps and scissors
Study NCT04129463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional trabeculotomy
Description: Conventional trabeculotomy in Buphthalmous using rigid Hans trabeculotome
Study NCT00993148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: 150 mg tab by mouth once daily for 96 weeks
Study NCT00993148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: 800 mg tab by mouth once daily for 96 weeks
Study NCT00993148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg capsule by mouth once daily for 96 weeks
Study NCT02792530 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary consultation
Description: Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
Study NCT04055623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
Description: For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections
Study NCT04055623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Monthly placebo infusions + 3 times per week placebo injections
Description: For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections
Study NCT04055623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
Description: For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.
Study NCT03805152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuronox(R)
Description: Injection botulinum toxin intramuscular for affected neck muscle
Study NCT03805152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport (R)
Description: Intramuscular injection
Study NCT02970162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine Phosphate
Study NCT02970162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study NCT00695097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab infusion on Day 1 and Day 15
Study NCT00695097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Rituximab
Description: No Rituximab
Study NCT02302339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glembatumumab vedotin
Study NCT02302339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glembatumumab vedotin and varlilumab
Study NCT02302339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
Study NCT02302339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glembatumumab vedotin and CDX-301
Study NCT00776074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin (GF)
Description: Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study NCT00776074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin (GC)
Description: Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study NCT03978546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Humphrey Visual Field Test
Description: SITA Standard and 24-2 and 10-2 visual field tests
Study NCT03978546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) Scan
Description: Circle and Wide Angle Scans
Study NCT03978546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Smart Perimetry - Henson 9000
Description: 24+10-2 Smart Supra test
Study NCT02177565 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: carrier plus in vitro expanded autologous BMSCs
Description: The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
Study NCT02177565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carrier plus in vitro expanded autologous BMSCs
Description: The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
Study NCT01538758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Us guided needling
Description: Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance.
Study NCT01538758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection
Description: Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
Study NCT02932852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lipoaspiration
Description: The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
Study NCT02932852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation
Description: The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
Study NCT03767413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNF
Description: proprioceptive neuromuscular facilitation training
Study NCT03767413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNFMP
Description: proprioceptive neuromuscular facilitation training and mental practice technique
Study NCT00829504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole HCl 0.25 mg Tablets
Description: 1 x 0.25 mg
Study NCT00829504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Requip® 0.25 mg Tablets
Description: 1 x 0.25 mg
Study NCT03622476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concentrated FVIII
Description: Intervention if the assessment considers that the treatment is inadequate
Study NCT03983356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
Study NCT01539460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgery
Description: Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
Study NCT01469611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.